Press Release FeedGet the RSS feed
Menu

Business Wire

Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)

AstraZeneca

Elecoglipron is an investigational oral small molecule GLP-1 receptor agonist discovered by Eccogene and licensed to AstraZeneca outside Greater China in November 2023.

Eccogene has earned $295 million to date under its collaboration with AstraZeneca and remains eligible to receive future milestones as well as royalty payments.

BOSTON & SHANGHAI, September 28, 2026--Eccogene, a global clinical-stage biotechnology company developing therapies for cardiometabolic diseases and inflammatory disorders, today announced that it has received a $50 million milestone payment from AstraZeneca. The milestone payment was triggered by the initiation of the global Phase 3 clinical program of elecoglipron (AZD5004/ECC5004).

Elecoglipron is an investigational, once-daily, oral small molecule GLP-1 receptor agonist for the treatment of cardiometabolic diseases. The elecoglipron Phase 3 program includes the Embold Phase III trials which will evaluate elecoglipron as treatment for people with obesity or overweight, with and without type 2 diabetes. The Eluminate Phase III trials will evaluate elecoglipron, as monotherapy and in combination with dapagliflozin, as treatment for people with type 2 diabetes. Two additional indication-seeking outcome trials (Elevate) will evaluate elecoglipron as treatment for people with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF), and chronic kidney disease (CKD), on the background of dapagliflozin plus other standard of care.

The initiation of the global Phase 3 program follows positive topline results from the Phase 2b VISTA and SOLSTICE trials, which demonstrated an 11.8% weight loss at 36 weeks​ in adults with obesity or overweight (with at least one weight-related comorbidity) and a 1.9% HbA1c reduction at 26 weeks​ in adults with type 2 diabetes, respectively. These results were presented at the American Diabetes Association 2026 Scientific Sessions in New Orleans and simultaneously published in The Lancet (VISTA, SOLSTICE).

"Elecoglipron entering Phase 3 is the moment our team has been building toward since we first discovered this molecule," said Jingye Zhou, Ph.D., Chief Executive Officer of Eccogene. "Elecoglipron was born out of our internal research, and its progression into an extensive global Phase 3 program with the strong leadership of AstraZeneca, is a direct result of that work and a meaningful step toward new oral options for people living with obesity/overweight, type 2 diabetes, heart failure and CKD."

  1. AIinsitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and CardiomyopathiesCompanies: AstraZenecaCollaboration applies insitro's Virtual Human causal AI discovery platform to two diseases defined by patient heterogeneity and high unmet medical need insitro to receive $40 million upfront and up to approximately $1.46 billion in potential discovery, development, and commercial milestones, and tiered royalties SOUTH SAN
  2. FinanceGuardant Health, Inc.Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast CancerCompanies: AstraZenecaPALO ALTO, Calif., October 08, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca’s next-generation oral selective estrogen
  3. FinanceSummit Therapeutics Inc.AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit TherapeuticsCompanies: AstraZenecaMIAMI, September 28, 2026--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve).